LGALS3 and metabolic dysfunction-associated steatohepatitis: Indeed, both the Gal-3 inhibitors GR-MD-02 and GB1211 are in evaluation for liver fibrosis in non-alcoholic steatohepatitis (NASH) [143,191,192].